Skip to main content
PHAR logo

Pharming Group N.V.

PHARNASDAQHealthcareBiotechnology

$9.36Today:- (-)1Y −31.21%

As of Oct 16, 2026 close

Market cap
$641.41M
P/E (TTM)
69.45
Forward P/E
145.69
Dividend yield
-
52-week range
$9.32$21.34
Volume (live)
-
Avg. volume (3M)
27.45K

Pharming Group (PHAR) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Pharming Group had a P/E ratio of 402.37, return on equity of 1.0% (up from -5.4%), debt-to-equity of 0.42 (down from 0.51) and a current ratio of 2.59 (down from 3.77). A current ratio of 2.59 means current assets exceed current liabilities.

Pharming Group Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income StatementBalance SheetCash FlowRatios
Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio402.37--55.2735.7526.30
P/S Ratio3.052.193.113.682.884.68
P/B Ratio4.142.943.493.692.965.41
Price/Tangible Book8.104.065.175.825.2310.47
Price/FCF21.26--35.8521.1012.57
Price/OCF20.97--33.6615.1111.87
Enterprise Value Ratios
EV/Revenue2.962.052.973.412.784.54
EV/EBITDA28.07188.69-40.9718.2211.66
EV/EBIT33.94--67.7023.0712.62
EV/FCF20.61--33.2920.4312.19
Profitability & Returns
Return on Equity (ROE)1.02%-5.38%-4.98%6.88%8.50%25.10%
Return on Assets (ROA)4.55%-0.52%-3.06%1.57%3.68%14.14%
Return on Invested Capital (ROIC)3.41%-2.10%-12.76%5.79%10.98%54.07%
Return on Capital Employed (ROCE)8.50%-1.10%-5.70%2.80%6.80%22.30%
Leverage & Solvency Ratios
Debt/Equity0.420.510.780.810.840.88
Debt/EBITDA2.6917.02-8.464.881.92
Debt/FCF2.15--7.915.972.05
Liquidity Ratios
Current Ratio2.593.774.064.655.333.42
Quick Ratio1.972.963.283.904.693.08
Efficiency Ratios
Asset Turnover0.840.690.550.500.490.63
Inventory Turnover0.750.630.510.500.871.26
Yield & Distribution Ratios
Earnings Yield0.25%-1.82%-1.38%1.81%2.80%3.80%
FCF Yield4.70%-0.40%-2.46%2.79%4.74%7.95%
Buyback Yield-11.25%-2.18%7.09%-0.85%-2.70%-1.37%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Pharming Group Financial Ratios

What is Pharming Group's P/E ratio?

Pharming Group's P/E ratio was 402.37 for fiscal 2025 (period ended Dec 31, 2025).

What is Pharming Group's return on equity?

Pharming Group's return on equity (ROE) was 1.0% for fiscal 2025 (period ended Dec 31, 2025). It was -5.4% a year earlier.

What is Pharming Group's debt-to-equity ratio?

Pharming Group's debt-to-equity ratio was 0.42 for fiscal 2025 (period ended Dec 31, 2025). It was 0.51 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition